Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab with induction chemotherapy and concurrent chemoradiotherapy for locally advanced head and neck squamous cell carcinoma
ChiCTR2500100598Phase 4Recruiting
- Sponsor
- Affiliated Cancer Hospital of Nanjing Medical University
- Start
- Apr 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of adebrelimab in head and neck squamous cell carcinoma (HNSCC) and nasopharyngeal carcinoma (NPC) (2 arms), sponsored by Affiliated Cancer Hospital of Nanjing Medical University. Primary endpoint: Objective response rate. Started Apr 2025; status: recruiting.
02
Drugs
adebrelimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR2500100598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500100598.